Amphetamine Stimulant denied as non-formulary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for amphetamine stimulant are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Amphetamine Stimulants as Non-Formulary — and How to Appeal

Formulary denials occur when the specific amphetamine stimulant your prescriber requested is not included on UnitedHealthcare's covered drug list for your plan, or is placed on a tier that requires prior authorization or has no coverage pathway. This frequently affects branded formulations when a generic equivalent exists on formulary, or newer extended-release or prodrug formulations that have not yet been added to UHC's preferred list. The plan's position is that a formulary alternative exists — but your prescriber may have strong clinical reasons why the non-formulary medication is necessary for you specifically.

Formulary exception appeals are a well-established pathway, and UHC is required by federal law to have a process for them.

## Your Federal Appeal Rights

• Formulary exception request: Before or alongside a formal appeal, your prescriber can submit a formulary exception request demonstrating that the formulary alternatives are clinically inappropriate for you. This is often the fastest route.
• Internal appeal (ERISA §503): If the exception is denied, you have the right to a full-and-fair internal review. The plan must explain why the non-formulary medication was denied and what alternatives it considered.
• External review (ACA §2719): If the internal appeal fails, file for independent external review within the window stated in your denial letter (typically approximately 180 days from final internal denial).
• Expedited review: Available for urgent situations; plans typically must respond within 72 hours.

## Documentation to Gather

1. Diagnosis and clinical context — Records confirming the diagnosis (e.g., ADHD) and the clinical severity or complexity that informs the prescriber's choice. 2. Formulary-alternative trial history — Documentation of every formulary-listed stimulant that was tried, the dates of use, outcomes, and the clinical reason each was inadequate or not tolerated. 3. Prescriber medical-necessity and exception letter — A letter from the treating physician explaining why the specific non-formulary medication is medically necessary and why available formulary alternatives are clinically inappropriate for this patient. 4. FDA prescribing label alignment — The prescriber should note that the requested medication is FDA-approved for the diagnosed condition, confirming this is not an off-label request. 5. Functional-impact documentation — Chart notes or patient-reported outcomes showing how inadequate prior therapy affected the patient's daily functioning.

## Criteria-Mapping Strategy

Request UHC's formulary exception criteria and any relevant clinical coverage policy. For each exception criterion, provide a direct chart-based answer. If the denial asserts that a formulary alternative is therapeutically equivalent, your prescriber's letter should address that assertion specifically — citing clinical differences in formulation, delivery, or individual response — so the reviewer cannot simply re-assert equivalence without engaging with the evidence.